Ozone Pharmaceuticals

The OZON pharmaceutical company is a company of the domestic pharmaceutical market for the production of generics - analogues of proprietary medicines. The volume of production of ozone is more than 500 million as of February 2020.

Performance indicators

2023: Revenue growth by 4% to RUB 19.7 billion

The revenue of Ozone Pharmaceuticals in 2023 reached 19.7 billion rubles, which is 4% more than in the previous year. This growth is due to efficient work with customers and strict cost control. The company's report was published in June 2024.

According to the company, taking into account the adjustment of revenue in 2022 for the effect of abnormal demand, the growth rate was 12% year-on-year. Ozone's operating profit Pharmaceutics rose to 6.1 billion rubles, which is 12% more than in 2022. The analytical indicator EBITDA increased by 13% year-on-year, reaching 7.1 billion rubles, while the EBITDA margin was 36%.

𝓲

Unsplash

Net profit for 2023 increased by 10% and amounted to 4.0 billion rubles due to strong operating indicators and positive EBITDA dynamics. Net profit margin reached 20%, up 1 percentage point from a year ago. The company's capital expenditures increased by 3%, reaching 706 million rubles.

According to Ozone Pharmaceuticals, net debt at the end of 2023 decreased by 17% to 12.0 billion rubles. The ratio of net debt to adjusted analytical EBITDA decreased from 2.0x to 1.6x, which indicates the stable financial condition of the company.

According to the publication "Pharmaceutical Bulletin," in 2023, "Ozone Pharmaceuticals" began to form a single pharmaceutical holding, which included LLC "Ozone," LLC "Ozone Farm," LLC "Ozone Medica," LLC "Mabscale" and a number of other affiliated legal entities. This step will allow the company not only to consolidate resources, but also to significantly improve the efficiency of business management and improve market position.^[1]

History

2024

Carrying out IPOs

The company "Ozone Pharmaceuticals" successfully conducted an initial public offering (IPO) on the Moscow Exchange. Trading in shares under the ticker symbol OZPH began on October 17, 2024.

According to RBC, the placement took place along the upper border of the previously announced price range - ₽35 per share. During the IPO, the company raised ₽3,45 billion, including a base size of ₽3 billion and a stabilization package of ₽450 million. The capitalization of Ozone Pharmaceuticals at the time of the start of trading is estimated at ₽38,5 billion, taking into account the funds raised.

𝓲

Freepik

The collection of applications for participation in the placement took place from October 11 to 16, 2024. Investors were offered shares of an additional issue in the amount of up to 10% of the company's authorized capital. Demand from institutional and private investors has repeatedly exceeded the supply volume at the upper end of the price range.

The securities were distributed in the following proportion: 47% to institutional investors, 53% to private investors. Allocation for private investors was about 11%. In total, more than 40 thousand private investors were included in the share capital of Ozone Pharmaceuticals.

The company plans to use the funds raised during the IPO to implement a long-term development strategy, reduce the debt burden and other corporate goals.

According to the company, in the first half of 2024, its revenue grew by 63% and amounted to ₽12,6 billion. EBITDA increased 2.7 times year-on-year, reaching ₽5 billion, and EBITDA margin was 40%. Net profit grew 4.4 times and reached ₽2,9 billion.

Analysts of leading brokerage companies see growth potential in Ozone Pharmaceuticals shares. Kit Finance experts predict growth to ₽42 -43 per share, and Alfa-Bank estimated the company's fair value at ₽80 -100 billion, which suggests growth potential of more than 120^[2]

Construction of a plant for the production of cancer drugs in the SEZ Togliatti for 3.5 billion rubles

Ozone Pharmaceuticals Group Russian pharmaceutical , a manufacturer of drugs, has completed the first stage constructions of the production site "" in the Ozon Medica special economic zone. Representatives Togliatti of the Group reported this medical that to the portal Zdrav.Expert on July 30, 2024. According to them, the plant will have wide possibilities for the production of pharmaceutical forms, including the production of drugs of the maximum, fifth, toxicity category. More. here

Notes